Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of GW Pharmaceuticals plc (NASDAQ: GWPH) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of GW Pharmaceuticals plc (NASDAQ: GWPH)  concerning whether a series of statements by GW Pharmaceuticals plc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On January 10, 2016, it was reported that GW Pharmaceuticals disclosed material weakness in its internal control over financial reporting for the year ended September 30, 2015 and that the management lacked effective controls over the completeness and assessment of clinical trial accruals.

On this news, NASDAQ: GWPH has fallen as much 6% on January 11, 2016.

Based in Cambridge, United Kingdom, and founded in 1998 GW Pharmaceuticals a biopharmaceutical company, engaging in developing, and commercializing cannabinoid prescription medicines.

If you purchased shares of GW Pharmaceuticals plc (NASDAQ: GWPH) on or before January 10, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185